-
Agarwala SS et al.
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
J Clin Oncol 2004;22:2101-2107.
-
Allen I, Kupelnick B, Kumashiro M.
Efficacy of interleukin-2 in the treatment of metastatic melanoma-systematic review and meta-analysis.
Sel Cancer Thera 1998;1:168-173.
-
Atkins MB et al.
A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated Intergroup trial.
Proc Am Soc Clin Oncol 2003;22:708 (abstract 2847).
-
Atkins MB et al.
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Clin Cancer Res 2002;8:3075-3081.
-
Atkins MB et al.
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
J Clin Oncol 1999;17:2105-2116.
-
Avril MF et al.
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
J Clin Oncol 2004;22:1118-1125.
-
Awada A et al.
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Br J Cancer 2005;92:1855-1861.
-
Bajetta E et al.
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
J Clin Oncol 1994;12:806-811.
-
Bedikian AY et al.
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
Melanoma Res 2004;14:63-66.
-
Bleehen NM et al.
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
J Clin Oncol 1995;13:910-913.
-
Buzaid AC.
Strategies for combining chemotherapy and biotherapy in melanoma.
Cancer Control 2000;7:185-197.
-
Carmichael J et al.
A multicentre phase II trial of vindesine in malignant melanoma.
Eur J Cancer Clin Oncol 1982;18:1293-1295.
-
Carter RD et al.
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Cancer Treat Rep 1976;60:601-609.
-
Chapman PB et al.
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
J Clin Oncol 1999;17:2745-2751.
-
Chiarion Sileni V et al.
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Melanoma Res 2001;11:189-196.
-
Costanzi JJ et al.
Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Med Pediatr Oncol 1982;10:251-258.
-
Creagan ET et al.
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
J Clin Oncol 1999;17:1884-1890.
-
Danson S et al.
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
J Clin Oncol 2003;21:2551-2557.
-
Dorval T et al.
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Cancer 1999;85:1060-1066.
-
Dudley ME et al.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science 2002;298:850-854.
-
Eigentler TK et al.
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.
Lancet Oncol 2003;4:748-759.
-
Eton O et al.
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
J Clin Oncol 2002;20:2045-2052.
-
Falkson CI et al.
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
J Clin Oncol 1998;16:1743-1751.
-
Flaherty LE et al.
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
J Clin Oncol 2001;19:3194-3202.
-
Gundersen S.
Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
Cancer Treat Rep 1987;71:997-999.
-
Hwu WJ et al.
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Cancer 2005;103:2590-2597.
-
Hwu WJ et al.
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
J Clin Oncol 2003;21:3351-3356.
-
Jacquillat C et al.
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
Cancer 1990;66:1873-1878.
-
Johnston SR et al.
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Br J Cancer 1998;77:1280-1286.
-
Jungnelius U et al.
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
Eur J Cancer 1998;34:1368-1374.
-
Karasarides M et al.
B-RAF is a therapeutic target in melanoma.
Oncogene 2004;23:6292-6298.
-
Keilholz U et al.
Dacarbazine, cisplatin and IFN-á2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951.
Proc Am Soc Clin Oncol 2003;22:708 (abstract 2848).
-
Keilholz U et al.
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
J Clin Oncol 1998;16:2921-2929.
-
Keilholz U et al.
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
J Clin Oncol 1997;15:2579-2588.
-
Legha SS et al.
Development of a biochemotherapy regimen with concurrent administration of cisplatin et al.
J Clin Oncol 1998;16:1752-1759.
-
Legha SS et al.
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Ann Oncol 1996;7:827-835.
-
Margolin K et al.
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
J Cancer Res Clin Oncol 2002;128:214-218.
-
McClay EF et al.
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Cancer Treat Rep 1987;71:465-469.
-
McDermott DF et al.
A phase II pilot trial of concurrent biochemotherapy with cisplatin et al.
Clin Cancer Res 2000;6:2201-2208.
-
Middleton MR et al.
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
J Clin Oncol 2000;18:158-166.
-
Miller RL et al.
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Cancer Res 1989;49:1871-1876.
-
Millward MJ et al.
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of longterm survival.
Proc Am Soc Clin Oncol 2004;23:708 (abstract 7505).
-
Morgan RA et al.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
J Immunol 2003;171:3287-3295.
-
Mornex F et al.
A prospective randomized multicentre phase III trial of fotemustine plus who le brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Melanoma Res 2003;13:97-103.
-
Nelimark RA et al.
Vindesine for metastatic malignant melanoma. A phase II trial.
Am J Clin Oncol 1983;6:561-564.
-
Pectasides D et al.
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Br J Cancer 1989;60:627-629.
-
Phan GQ et al.
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
J Clin Oncol 2001;19:3477-3482.
-
Richards JM et al.
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
J Clin Oncol 1999;17:651-657.
-
Ridolfi R et al.
Italian Melanoma Intergroup, Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
J Clin Oncol 2002;20:1600-1607.
-
Ringborg U et al.
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.
Med Oncol Tumor Pharmacother 1989;6:285-289.
-
Robinson WA et al.
Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.
Immunobiology 1986;172:275-282.
-
Rosenberg SA.
Progress in human tumour immunology and immunotherapy.
Nature 2001;411:380-384.
-
Rosenberg SA et al.
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
J Clin Oncol 1999;17:968-975.
-
Rosenberg SA et al.
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
JAMA 1994;271:907-913.
-
Seigler HF et al.
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
Cancer 1980;46:2346-2348.
-
Smith KA, Green JA, Eccles JM.
Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma.
Eur J Cancer 1992;28:438-441.
-
Strumberg D et al.
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
J Clin Oncol 2005;23:965-972.
-
Verschraegen CF et al.
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
Cancer 1988;62:1061-1065.
-
Wang E et al.
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer Res 2002;62:3581-3586.
-
Wilhelm SM et al.
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res 2004;64:7099-7109.
-
York RM, Foltz AT.
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
Cancer 1988;61:2183-2186.
-
Young AM et al.
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
Clin Oncol (R Coll Radiol) 2001;13:458-465.
Bildatlas Hämatologie
Druckversion
ISSN: 2193-6021
Zum Seitenanfang